The loneliness epidemicsuper 8 paranaque 。

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights , underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases . This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cardiff Oncology, Inc. (NASDAQ: CRDF), Personalis, Inc. (NASDAQ: PSNL), Tempus AI, Inc. (NASDAQ: TEM), and Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031 —a clear indicator of oncology's rapid growth and critical importance. Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers, which were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025 . "We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer," said Tom Heineman , M.D., Ph.D., Chief Medical Officer of Oncolytics . "Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devasting diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients." Oncolytics will present two key data sets from the GOBLET study, with preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab presented in Poster Session C on January 25, 2025 , from 7:00 to 7:55 a.m. PT . Additionally, results from the safety run-in phase for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, with and without atezolizumab will be presented in Poster Session B on January 24, 2025 , from 11:30 a.m. to 1:00 p.m. PT . Both abstracts will be available on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 . CONTINUED... Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024 , data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient's tumor scan. "We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial," said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology . "Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses." Personalis, Inc. (NASDAQ: PSNL), a developer of advanced cancer genomic tests and analytics, and Tempus AI, Inc. (NASDAQ: TEM), an AI-powered healthcare technology company, recently announced they've expanded their commercial relationship. Both companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. "While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products," said Chris Hall , CEO of Personalis . "We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity." Under this expanded relationship, Tempus will be enabled to offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study. Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), a commercial-stage immunotherapy and targeted oncology company focused on novel treatments for patients with solid tumor cancers, recently announced that the FDA approved its UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. "[This] FDA approval of UNLOXCYT – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced cSCC," said James Oliviero , President and CEO of Checkpoin t. "This approval marks Checkpoint's transformation to a commercial-stage company, with the opportunity to compete in a U.S. market estimated to exceed $1 billion annually, where we believe UNLOXCYT offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than programmed death receptor-1 (PD-1), to release the inhibitory effects of PD-L1 on the anti-tumor immune response. Additionally, UNLOXCYT has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), another potential differentiating feature of the drug compared to existing marketed therapies for patients with cSCC." Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content: https://www.prnewswire.com/news-releases/oncology-advancements-accelerate-amid-rising-early-onset-cancer-diagnoses-302337555.html SOURCE USA News GroupSeeking Income, Finding Underperformance, This Time Courtesy Of JEPICOLUMBIA, South Carolina (AP) — Victims’ families and others affected by crimes that resulted in federal death row convictions shared a range of emotions on Monday, from relief to anger, after President Joe Biden commuted dozens of the sentences . Biden converted the sentences of 37 federal death row inmates to life imprisonment without the possibility of parole. The inmates include people convicted in the slayings of police and military officers, as well as federal prisoners and guards. Others were involved in deadly robberies and drug deals. Three inmates will remain on federal death row: Dylann Roof , convicted of the 2015 racist slayings of nine Black members of Mother Emanuel AME Church in Charleston, South Carolina; the 2013 Boston Marathon Bomber, Dzhokhar Tsarnaev , and Robert Bowers, who fatally shot 11 congregants at Pittsburgh’s Tree of life Synagogue in 2018 , the deadliest antisemitic attack in U.S history. Opponents of the death penalty lauded Biden for a decision they’d long sought. Supporters of Donald Trump , a vocal advocate of expanding capital punishment, criticized the move weeks before the president-elect takes office. Victims’ families and former colleagues share relief and anger Donnie Oliverio, a retired Ohio police officer whose partner, Bryan Hurst, was killed by an inmate whose death sentence was commuted, said the killer’s execution “would have brought me no peace.” “The president has done what is right here,” Oliverio said in a statement also issued by the White House. But Hurst’s widow, Marissa Gibson, called Biden’s move distressing and a “complete dismissal and undermining of the federal justice system,” in a statement to The Columbus Dispatch . Tim Timmerman, whose daughter, Rachel, was thrown into a Michigan lake in 1997 to keep her from testifying in a rape trial, said Biden’s decision to commute the killer’s sentence offered families “only pain.” “Where’s the justice in just giving him a prison bed to die comfortably in?” Timmerman said on WOOD-TV. Heather Turner, whose mother, Donna Major, was killed in a 2017 South Carolina bank robbery, called the commutation of the killer’s sentence a “clear gross abuse of power” in a Facebook post. “At no point did the president consider the victims,” Turner wrote. “He, and his supporters, have blood on their hands.” Corey Groves, whose mother, Kim Groves, was murdered in a 1994 plot by a New Orleans police officer after she filed a complaint against him, said the family has been living with the “nightmare” of her killer for three decades. “I have always wanted him to spend the rest of his life in prison and have to wake up every morning and think about what he did when he took our mother from us,” Groves said in a statement through his attorney. Decision to leave Roof on death row met with conflicting emotions Families of the nine people killed and the survivors of the massacre at the Mother Emanuel AME Church have long had a broad range of opinions on Roof’s punishment. Many forgave him, but some say they can’t forget and their forgiveness doesn’t mean they don’t want to see him put to death for what he did. Felicia Sanders survived the shooting shielding her granddaughter while watching Roof kill her son, Tywanza, and her aunt, Susie Jackson. Sanders brought her bullet-torn bloodstained Bible to his sentencing. In a text message to her lawyer, Andy Savage, Sanders called Biden’s decision to not spare Roof’s life a wonderful Christmas gift. Michael Graham, whose sister, Cynthia Hurd, was killed, told The Associated Press that Roof’s lack of remorse and simmering white nationalism in the country means he is the kind of dangerous and evil person the death penalty is intended for. “This was a crime against a race of people,” Graham said. “It didn’t matter who was there, only that they were Black.” But the Rev. Sharon Risher, who was Tywanza Sanders’ cousin and whose mother, Ethel Lance, was killed, criticized Biden for not sparing Roof and clearing out federal death row. “I need the President to understand that when you put a killer on death row, you also put their victims’ families in limbo with the false promise that we must wait until there is an execution before we can begin to heal,” Risher said in a statement. Risher, a board member of Death Penalty Action, which seeks to abolish capital punishment, said during a Zoom news conference that families “are left to be hostages for the years and years of appeals that are to come.” Abraham Bonowitz, Death Penalty Action’s executive director, said Biden was giving more attention to the three inmates he chose not to spare, something they all wanted as a part of their political motivations to kill. “When Donald Trump gets to execute them what will really be happening is they will be given a global platform for their agenda of hatred,” Bonowitz said. Politicians and advocacy groups speak up Biden had faced pressure from advocacy organizations to commute federal death sentences, and several praised him for taking action in his final month in office. Anthony D. Romero, executive director of the ACLU, said in a statement that Biden has shown “the brutal and inhumane policies of our past do not belong in our future.” Republicans, including Sen. Tom Cotton of Arkansas, criticized the move — and argued its moral ground was shaky given the three exceptions. “Once again, Democrats side with depraved criminals over their victims, public order, and common decency,” Cotton wrote on X. “Democrats can’t even defend Biden’s outrageous decision as some kind of principled, across-the-board opposition to the death penalty since he didn’t commute the three most politically toxic cases.” One inmate’s attorney expresses thanks — and his remorse Two men whose sentences were commuted were Norris Holder and Billie Jerome Allen, on death row for opening fire during a 1997 bank robbery in St. Louis, killing a guard, 46-year-old Richard Heflin. Holder’s attorney, Madeline Cohen, said in an email that Holder, who is Black, was sentenced to death by an all-white jury. “Norris’ case exemplifies the racial bias and arbitrariness that led the President to commute federal death sentences,” Cohen said. “Norris has always been deeply remorseful for the pain his actions caused, and we hope this decision brings some measure of closure to Richard Heflin’s family.” But Ed Dowd Jr., the U.S. attorney in St. Louis at the time of the robbery and now a private attorney, criticized Biden’s move. “This case was a message to people who wanted to go out and shoot people for the hell of it, that you’re going to get the death penalty,” Dowd said. Now, “Biden is sending a message that you can do whatever you want and you won’t get the death penalty.” This story has been updated to correct the spelling of Rev. Sharon Risher’s name. Swenson reported from Seattle. Associated Press writers Sara Cline in Baton Rouge, Louisiana; Jim Salter in O’Fallon, Missouri; Stephen Smith in New Orleans, and Corey Williams in Detroit contributed.ATLANTA , Dec. 23, 2024 /PRNewswire/ -- KORE Group Holdings, Inc. (NYSE: KORE) ("KORE" or the "Company"), the global pure-play Internet of Things ("IoT") hyperscaler and provider of IoT Connectivity, Solutions, and Analytics, today announced it has received notification (the "Acceptance Letter") from the New York Stock Exchange (the "NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual relating to minimum market capitalization and stockholders' equity. In the Acceptance Letter, the NYSE granted the Company an 18-month period from September 12, 2024 (the "Plan Period") to regain compliance with the continued listing standards. As part of the Plan, the Company is required to provide the NYSE quarterly updates regarding its progress towards the goals and initiatives in the Plan. In the Plan, Kore included details regarding previously reported operational restructuring activities, as well as an outlook on the Company's business. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. Top trending stories from the past week. News, Sports, and more throughout the week. The week's obituaries, delivered to your inbox.

Providence, Oklahoma hope key players are back in Bahamas

UK areas most at risk of cybercrime

If you are in the process of building an investment portfolio, then having a few ASX 200 in there could be a good starting point. But which blue chip shares could be buys? Let's take a look at four quality options that analysts currently rate as buys. They are as follows: ( ) Brambles could be an ASX 200 blue chip share to buy according to analysts. It is a supply chain solutions company that manages the world's largest pool of reusable pallets, crates, and containers. The team at Ord Minnett is bullish on the company. It believes that Brambles is well-placed for growth due partly to its Serialisation Plus plan, which is aiming to make its operations more efficient. The broker currently has a buy rating and $20.60 price target on Brambles' shares. ( ) Another ASX 200 blue chip share that could be a buy is Flight Centre. It is the travel company operating the iconic Flight Centre brand, as well as the Aunt Betty, Corporate Traveller, FCM, Stage & Screen, and Travel Associates brands. Macquarie is a fan of the company and believes that its shares are undervalued following recent weakness. Especially given its belief that things will get easier for Flight Centre as FY 2025 progresses following a soft start. The broker has an outperform rating and $22.34 price target on its shares. ( ) A third ASX 200 blue chip share that analysts are tipping as a buy is Goodman Group. It is a leading integrated commercial and industrial property company. Goodman owns, develops, and manages high-quality, sustainable properties that are close to consumers and provide essential infrastructure for the digital economy. It also has growing and meaningful exposure to the booming data centre market. The team at Morgan Stanley is bullish on the company and continues to forecast solid earnings growth in the coming years. The broker has an overweight rating and $42.40 price target on its shares. ( ) A final ASX 200 blue chip share that could be a top buy according to analysts is Treasury Wine. It is a leading wine company that owns a portfolio of popular brands. This includes the Penfolds, Wolf Blass, Lindeman's, DAOU Vineyards, and 19 Crimes brands. The team at Morgans thinks the market is undervaluing its shares at present. Especially given the potential of its recent acquisition of DAOU Vineyards. It notes that the "acquisition is in line with TWE's premiumisation and growth strategy and will strengthen a key gap in Treasury Americas (TA) portfolio" and that "if TWE delivers on its investment case, there is material upside to our valuation." Morgans currently has an add rating and $14.80 price target on its shares.Spot the difference: A $185m surrealist masterpiece and its sister displayed here

Jimmy Carter: Many evolutions for a centenarian ‘citizen of the world’

Surgical Gloves Market Size: Strong Growth Ahead (2024-2032)Manchester United manager Ruben Amorim has questioned the “choices” of those close to forward Marcus Rashford, whose time at Old Trafford could be coming to an end. Get all the latest football news, highlights and analysis delivered straight to your inbox with Fox Sports Sportmail. Sign up now!!! The 27-year-old England international sat out a third straight game on Sunday as United slumped to a 3-0 home loss to Bournemouth. Rashford was also omitted from the squad for the derby win at Manchester City earlier this month and Thursday’s League Cup quarter-final defeat by Tottenham. Two days before the Spurs loss, Rashford said in an interview that he was “ready for a new challenge and the next steps” of a career that began in the United academy. “It is a hard situation but I understand that this kind of player have a lot of people around them, and making some choices that sometimes is not the first idea from the player,” Amorim told Sky Sports on Monday. “They chose to do that interview because it’s not just Marcus. I understand that so for me as a coach I’m just focused on the performance, the way he trains. “The rest, I think, is better for me and the club to deal with that when the times comes.” Amorim also expressed his support for Rashford, who is under contract until 2028, and is keen for the player to stay at United. The Portuguese said he can “separate” his relationship with Rashford, who has scored 87 goals in 287 appearances for the club, from the decisions of the people advising him. “At the moment I’m just focused on improving Marcus,” added Amorim. “We need a lot in this moment, (from a) talented guy like Marcus, and I forget for now the interview. I just see what I see on the pitch.” Former Liverpool and England defender Stephen Warnock believes the situation is far more complicated than Amorim’s justification of performance and training standards. The 27-year-old is United’s joint top-scorer in the Premier League this season alongside Bruno Fernandes with four goals, while he has netted three more goals across the Europa League and Carabao Cup, but has been ridiculed for his lack of intensity without the ball. That is not the real issue, according to Warnock however, with Rashford, who scored three goals for England at the 2022 World Cup, is being “made a scapegoat” for other issues at United. “What we’ve seen behind the scenes is there’s been a lot of cost cutting,” Warnock said on Sky Sports. “But what we also know is, he’s potentially their biggest earner. “Now, is that the ownership coming in going ‘absolutely not, we’re going to set wage structure and make sure we bring that down. He’s the first one that’s got to go or we’re going to have to do something about it’. “How do you do that? You frustrate a player. You make life difficult for him. “I’ve been in that situation where someone’s come in and gone ‘you’re not a player for me, so what I’m going to do is, I’m going to make life hell for you. I’m going to make it really embarrassing for you. I’m going to change the way we do everything. You’re training and I’m going to leave you out of the squads, and I’m going to make it so that you train all the week but you get no reward at the end of it’. “I get that sense at the moment that he’s in that, sort of, place at the moment where he’s being made the scapegoat.” Meanwhile former Manchester United defender Gary Neville has all but given up hope that the issues between Rashford and the club can be resolved. For Neville, who spent his entire career at Old Trafford and made 400 appearances for the club, the Rashford problem tugs on his heart strings as he too was an Academy player at United and was part of a generation of remarkable success under Sir Alex Ferguson during the 1990s and 2000s alongside fellow academy graduates like his brother Phil, David Beckham, Paul Scholes and Ryan Giggs. Rashford is Manchester and born-raised and has been a much-loved figure in the city in England’s north for his charity work helping feed children in poverty who were no longer receiving their free school meals during Covid-19 lockdowns, as well as donating essential items to homeless people. He was appointed a Member of the Order of the British Empire in 2020 for his ongoing efforts, and Neville is saddened by the rift that has emerged between the club and a player who has been an outstanding part of the community in which it is based. “I don’t think academy players, who have great talent like Marcus, should ever leave the club,” Neville said on Sky Sports. “You want to see players at the club who have been there since they were eight stay there forever. “But I think now in the past few days, it’s got to the point where it may be better for both parties for it to end quite quickly. “Who knows, it might resolve itself. Ruben Amorim is saying that right things but I suspect behind the scenes it’s difficult.” United’s defeat by Bournemouth left them 13th in the Premier League, their lowest position in the top flight at Christmas since 1986. Amorim’s side return to action at Wolves on Boxing Day before hosting Newcastle next Monday.

Pregnant reality TV star ‘rushed to hospital’ days after home robbery attempt

How a GoPro camera has helped the Vikings keep rookie quarterback J.J. McCarthy on trackFlorida social media influencer arrested after police say she filmed herself while shoplifting - USA TODAYToll Brothers Announces Final Opportunity at Verona Estates Community in Chatsworth, California

Adani to buy plane maintenance co Air Works for Rs 400 crore

Another one! The Container Store files for bankruptcy; this is what we knowFormer U.S. President Bill Clinton was admitted to a Washington -area hospital on Monday. “President Clinton was admitted to Georgetown University Medical Center this afternoon for testing and observation after developing a fever,” Clinton’s deputy chief of staff Angel Ureña wrote on X. “He remains in good spirits and deeply appreciates the excellent care he is receiving.” “The former president will be fine,” a source close to Clinton told NBC News. “He developed a fever and wanted to be checked out. He is awake and alert.” Clinton, 78, was at home in Washington when he was taken to the hospital, CNN reports . The former president was hospitalized with a non-Covid infection that spread to the blood stream in 2021. He also has a history of cardiac issues, requiring a stent to open an artery in 2010 and a quadruple bypass heart surgery in 2004. Throughout the fall, Clinton campaigned on behalf of fellow Democrat Vice President Kamala Harris in her ultimately unsuccessful race against Donald Trump . On the trail, Clinton hammered Trump and made the occasional joke about his own age. “Two days ago I turned 78 – the oldest man in my family,” Clinton told the Democratic National Convention in August. “And the only personal vanity I want to assert, is that I’m still younger than Donald Trump.” “[H]ow does Donald Trump use his voice? Mostly to talk about himself—his vengeance, vendettas, complaints, conspiracies,” the former president added. “The next time you hear him, don’t count the lies, count the I’s. He’s like the tenor warming up before the opera: me, me, me, me.” Clinton’s name also surfaced during lighter fare this year, when actor Gwyneth Paltrow told the long-running YouTube series Hot Ones that Clinton very publicly fell asleep during a screening of her 1996 film Emma at the White House. “True – he was snoring right in front of me,” Paltrow said . In November, Clinton published a memoir, Citizen , about his time in public life after leaving the presidency.Leishen Energy Holding Co., Ltd. Announces Closing of $5,500,000 Initial Public OfferingThe FDA approved acellular tissue engineered vessel-tyod (Symvess, Atev; Humacyte Inc) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible. The approval follows positive results from the pivotal phase 2/3 V005 (NCT03005418) clinical trial. Image credit: JHVEPhoto | stock.adobe.com Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma NCT03005418 Humacyte, Inc. September 1, 2027 Symvess is a first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial replacement and repair. Because harvesting vein from a trauma patient can take time during surgery, Symvess is available off-the-shelf, which does not require potential further injury to the patient to obtain vascular repair material via an invasive surgery. The Symvess trauma program was granted regenerative medicine advanced therapy designation by the FDA in May 2023, and in February 2024, it received a priority review. “The approval of a vascular conduit that resists infection and remodels into native arteries is an extraordinary technological advancement that will have a huge impact on the quality of trauma care around the world,” Charles J. Fox, MD, FACS, director of Vascular Surgery at the University of Maryland Capital Region, said in a news release. “Symvess is perfectly sized to treat most injuries, has excellent handling properties, and reduces time necessary to save both life and limbs.” The V005 (NCT03005418) trial, also called CLN-PRO-V005, is a prospective, multicenter, multi-cohort, non-randomized phase 2/3 study which enrolled patients with life- or limb-threatening vascular trauma which requires surgical repair. A limb cohort includes patients who require repair of a vessel contained to the upper or lower extremity, and a torso cohort includes patients who require repair of vessels within the thorax (excluding the heart), abdomen, and retroperitoneum. No control arms are included in this study. All patients received the investigational Symvess, which were used for arterial bypass or reconstruction. The device is implanted using a standard vascular surgical technique, similar to those used to place predicate peripheral vascular prostheses. The primary outcome measures are primary patency (defined as the interval from the time of access placement until any intervention designed to maintain or reestablish patency, access thrombosis or the measurement of patency), which was assessed at 30 days, and frequency and severity of adverse events (AEs), which was assessed at 36 months. A total of 69 patients with a mean age of 33.5 years were enrolled in the trial, of which the majority were male (n = 38). At day 30, the primary patency was approximately 84.3% (95% CI, 72.0%-91.8%) and secondary patency was 90.2% (95% CI, 79.0%-95.7%). Additionally, amputation rate was about 9.8% (95% CI, 4.3%-21.0%). Infection and death rates were also low, occurring in about 2.0% (95% CI, 0.4%-10.3%) and 5.9% (95% CI, 2.0%-15.9%) of patients, respectively. “I believe that Symvess will revolutionize vascular trauma care and be profoundly beneficial to our patients,” Rishi Kundi, MD, surgical critical care of vascular surgery at the University of Maryland Medical System, said in the news release. “From my experience so far, Symvess will allow reconstructions that are currently impracticable because of contamination and infection. It will make reconstructions that we now perform with prosthetic or even biologic grafts more successful.” Overall, AEs and serious AEs were frequent in V005 consistent with patients with acute injuries. According to the investigators, AEs of special interest, including thrombosis, rupture, aneurysm, and pseudoaneurysm, occurred at acceptable rates that were consistent with reports of other vascular conduits, including autologous vein and synthetic grafts. At 30 days, AEs of interest were reported for 8 patients and included thromboses and occlusions (resolved or unresolved), nonspontaneous rupture (n = 1), and infection of the conduit (n = 1). Additionally, all enrolled patients receiving Symvess presented multiple risk factors that could lead to wound infection, of which 20 patients developed 1 or more infectious events by day 30 (eg, bacteremia, fungemia, sepsis, and osteomyelitis). “The FDA approval of Symvess will make it the preferred conduit for complex vascular injuries, and particularly those at risk for infection,” Ernest E. Moore, MD, FACS, director of Research at the Ernest E. Moore Shock Trauma Center at Denver Health, said in the news release.

Luton, Bedfordshire, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The adoption of 3D printing in the automotive sector is reshaping vehicle development by enabling the production of complex, lightweight, and high-performance components. This technology uses computer-aided design (CAD) models to create intricate parts, improving vehicle efficiency, optimizing performance, and reducing production costs. Key growth drivers include the demand for lighter parts, faster prototyping, and the ability to customize components for specific vehicle needs. Sustainability is another factor, as 3D printing reduces material waste. Advancements in materials and technology are expanding 3D printing's application to metals, ceramics, and composites, further driving adoption. Access PDF Sample Report (Including Graphs, Charts & Figures) @ https://exactitudeconsultancy.com/reports/33192/3d-print-in-automotive-additive-manufacturing-market/#request-a-sample The 3D printing market in automotive manufacturing is projected to reach USD 10 billion by 2028, driven by the need for custom parts and rapid prototyping, with partnerships between automakers and 3D printing companies accelerating this growth. The technology's ability to reduce waste and enhance production efficiency aligns with sustainability goals, ensuring its expanding role in the industry. The global 3D printing market in automotive is segmented by material, technology, component, application, and region, highlighting the diverse applications and innovations in this field. Material Segmentation: The market is predominantly driven by metal, which holds a 60-65% share of the market. Metals, including stainless steel, titanium, and aluminum, are favored for their strength, durability, and heat resistance. These materials are crucial for the production of high-performance components such as engine parts, chassis, and structural elements, where precision and performance are paramount. Technologies such as Electron Beam Melting (EBM) and Selective Laser Melting (SLM) are commonly used to process these metals, enabling the creation of complex geometries and intricate designs that meet automotive specifications. Polymers , with a 25-30% market share, represent the second most widely used material. Polymers such as ABS, PLA, and nylon are more cost-effective and lightweight compared to metals, making them ideal for creating prototypes and components requiring flexibility and impact resistance. These materials are commonly used in the development of non-structural parts or for fast prototyping. Ceramics , while holding a 5% market share, are expected to experience the highest growth in the coming years. Ceramics, including alumina, zirconia, and silicon carbide, are used for their exceptional heat tolerance and wear resistance, particularly in high-performance applications like turbochargers and brake systems. Technology Segmentation: The Fused Deposition Modeling (FDM) technology dominates the market with 50-55% market share. Known for its cost-effectiveness and ease of use, FDM is particularly popular for producing prototypes and functional parts. This technology is capable of working with a variety of thermoplastic materials, offering versatility for automakers looking to optimize both design and production costs. Selective Laser Sintering (SLS) comes in second with 20-25% of the market share. SLS produces parts with greater precision and strength compared to FDM but at a higher cost. Its ability to create high-performance parts and more accurate geometries makes it particularly suitable for end-use components. Digital Light Processing (DLP) , with a 10-15% share, is a newer technology that has gained popularity due to its precision and speed. While still emerging, DLP's capability to produce highly detailed parts quickly is making it a preferred option for automotive manufacturers. Stereolithography (SLA) accounts for around 5-10% of the market. Despite being a well-established technology, SLA's slower speed and higher costs limit its adoption compared to newer methods like DLP. The least popular technologies, Selective Laser Melting (SLM) and Electron Beam Melting (EBM), collectively hold a 5% share of the market. These metal 3D printing techniques are used primarily for producing high-performance parts in automotive applications requiring advanced material properties and precision. Component Segmentation: The market is also segmented by components, which include hardware, software, and services. Hardware holds the largest share, reflecting the significant investment in 3D printers and other equipment necessary for additive manufacturing. Software plays an essential role in the design and simulation processes, while services cover everything from prototyping to full-scale production support, contributing to the holistic value of the additive manufacturing ecosystem. Application Segmentation: Applications of 3D printing in the automotive industry are diverse, spanning production and prototyping/research and development. Prototyping remains a critical application, allowing automotive companies to reduce time-to-market by rapidly iterating on designs. As the technology evolves, production is gaining ground, with 3D printing enabling the manufacture of specialized, low-volume components cost-effectively, and enhancing the ability to create customized parts for niche automotive applications. Overall, the 3D printing market in automotive manufacturing is seeing continued growth, driven by advancements in materials and technology, and the increasing demand for lightweight, customized, and high-performance components. As automakers continue to prioritize efficiency, cost-effectiveness, and sustainability, 3D printing will play an increasingly pivotal role in reshaping automotive manufacturing processes. Drivers of 3D Printing in Automotive Additive Manufacturing: The growing demand for lightweight components is a significant driver in the adoption of 3D printing within the automotive sector. As automakers focus on improving fuel efficiency and reducing environmental impact, 3D printing enables the creation of complex structures that use less material while maintaining strength. This aligns with the industry's shift towards lightweighting to enhance vehicle performance. Furthermore, the design freedom offered by 3D printing allows for the production of intricate geometries and lattice structures, which are challenging to achieve with traditional manufacturing methods. The need for rapid prototyping in automotive design, which accelerates the development cycle and allows for iterative design changes, also supports the increasing use of this technology. Overall, 3D printing plays a crucial role in helping manufacturers meet sustainability and efficiency goals, thus driving market growth. Opportunities: 3D printing technology opens significant opportunities for customized automotive features, enabling the production of personalized car components. This includes everything from bespoke interior fittings to exterior trimmings, offering consumers the ability to tailor their vehicles to their specific tastes. Automakers can leverage this customization trend to provide unique, differentiated products, improving customer satisfaction and creating a competitive market edge. As consumer demand for personalization increases, 3D printing presents a cost-effective and innovative solution for meeting these expectations, further positioning it as a transformative force in the automotive sector. Trends in 3D Printing for Automotive Additive Manufacturing: Increased use of metal 3D printing : Metal 3D printing is gaining traction due to its ability to produce lightweight, durable, and high-performance parts, which is particularly important for the development of electric vehicles (EVs), where reducing weight is critical to increasing range. This segment accounts for over 50% of the market and is expected to see growth as the demand for EVs rises. Adoption of new 3D printing technologies : Technologies such as Continuous Liquid Interface Production (CLIP) are being adopted due to their ability to print parts significantly faster than traditional methods like SLA, which makes them ideal for high-volume production, such as car bumpers. This trend is projected to increase as demand for faster and more efficient production methods rises. Use of 3D printing for tooling production : 3D printing is revolutionizing the production of tooling, such as jigs and fixtures, by enabling faster and more cost-effective creation of custom tools without the need for traditional machining. This trend is expected to grow as companies look to reduce costs and lead times associated with tooling production. Integration into the design process : The integration of 3D printing into the vehicle design process is becoming more common, allowing for faster prototyping, iterative design modifications, and quicker time-to-market. This trend is expected to expand as automotive companies prioritize speed and efficiency in their design cycles. Development of 3D printing standards : The automotive industry is actively working on standardizing 3D printing processes to ensure that parts meet safety and quality requirements. These efforts will further boost the adoption of 3D printing in the sector as manufacturers gain confidence in the reliability and performance of 3D printed components. Report Link Click Here: https://exactitudeconsultancy.com/reports/33192/3d-print-in-automotive-additive-manufacturing-market/ Competitive Landscape 3D Systems HP Renishaw EOS GmbH Stratasys SLM Solutions Group AG Arcam AB Metal AM Additive Industries Materialise NV Concept Laser GmbH Farsoon Technologies Voxeljet AG NanoXplore BigRep GmbH Markforged Desktop Metal Prodways EnvisionTEC 3Diligent Recent Developments : 3D Systems' FDA Clearance for Cranial Implants (April 2023): 3D Systems received FDA 510(k) clearance for their VSP PEEK Cranial Implant, a breakthrough in 3D-printed cranial plates. This implant, designed to restore skull defects, uses PEEK (Polyether ether ketone), a high-performance polymer closely resembling human bone. This approval allows 3D Systems to offer this technology in the U.S., expanding the use of 3D printed cranial implants in medical procedures. The company has already produced nearly 40 cranial implants in Europe with this technology​. Salzburg University Hospital's 3D-Printed Occipital Prosthesis (March 2023): The University Hospital Salzburg successfully performed a groundbreaking surgery using a 3D-printed occipital prosthesis for a patient suffering from craniosynostosis. The implant was custom-designed using the patient's CT scan and produced with a 3D Systems Kumovis R1 printer. This procedure is part of Salzburg's push for advanced 3D printing applications in medicine​. Stratasys Partners with Toyota Racing Development (June 2022): Stratasys has formed a partnership with Toyota Racing Development (TRD) to integrate 3D printing into automotive manufacturing, specifically for the Toyota GR86. The collaboration aims to produce 3D-printed production parts for the GR Cup racing series, marking a significant advancement in the use of 3D printing for automotive applications Regional Analysis of the 3D Printing in Automotive Additive Manufacturing Market The Asia Pacific region is expected to experience substantial growth in the 3D printing market for the automotive sector in the coming years, positioning itself as the largest market globally. This growth is fueled by the region's strong manufacturing base, rapid technological advancements, and a growing emphasis on innovative production methods. Key countries such as China, Japan, and South Korea have been at the forefront of adopting 3D printing technologies in automotive production. The industry benefits significantly from the ability of 3D printing to accelerate prototyping processes, simplify manufacturing workflows, and facilitate the creation of lightweight components essential for improving vehicle efficiency and performance. With governmental initiatives supporting the expansion of additive manufacturing, the region continues to enhance its leadership in this transformative technology. As a result, Asia Pacific is positioned as a significant driver of growth in the global automotive 3D printing market, with the sector forecast to expand by over 30% annually. Europe ranks as the second-largest market for 3D printing in the automotive industry, driven by widespread adoption in major automotive manufacturing nations, particularly Germany and the UK. These countries are at the forefront of utilizing additive manufacturing for sophisticated automotive solutions, including the development of customized components, rapid prototyping, and advanced manufacturing techniques. Europe's automotive sector has embraced 3D printing due to its ability to streamline the production process and offer high levels of precision and personalization. With strong commitments to innovation and sustainability, the European market is expected to maintain its pivotal role in shaping the future of 3D printing applications in the automotive industry. The European market share is anticipated to grow at a compound annual growth rate (CAGR) of around 20%, fueled by continuous investment in both research and development and the adoption of advanced manufacturing technologies. Market Segmentations: 3D Print in Automotive Additive Manufacturing Market by Material Metal Polymer Ceramic 3D Print in Automotive Additive Manufacturing Market by Technology Selective Laser Sintering (SLS) Fused Deposition Modeling (FDM) Digital Light Processing (DLP) Stereo Lithography (SLA) Electron Beam Melting (EBM) Selective Laser Melting (SLM) 3D Print in Automotive Additive Manufacturing Market by Component Hardware Software Services 3D Print in Automotive Additive Manufacturing Market by Application Production Prototyping/R&D 3D Print in Automotive Additive Manufacturing Market by Region North America Europe Asia Pacific South America Middle East and Africa Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/33192/3d-print-in-automotive-additive-manufacturing-market/#request-a-sample Related Reports: Shipping Container Market https://exactitudeconsultancy.com/reports/2769/shipping-container-market/ The global shipping container market size is expected to grow at 4% CAGR from 2022 to 2029. It is expected to reach above USD 10.66 billion by 2029 from USD 7.48 billion in 2020. Tractor Engines Market https://exactitudeconsultancy.com/reports/4508/tractor-engines-market/ The global tractor engine market size is estimated at USD 12.7 billion in 2020 and is projected to reach USD 23.9 billion by 2029, at a CAGR of 7.3% for the forecasted years 2022 to 2029. Automotive Filters Market https://exactitudeconsultancy.com/reports/1754/automotive-filters-market/ The global automotive filter market is expected to grow at 3.95% CAGR from 2019 to 2028. It is expected to reach above USD 22.4 billion by 2028 from USD 18.00 billion in 2019. Electric Ships Market https://exactitudeconsultancy.com/reports/2197/electric-ships-market/ The global Electric Ships Market is expected to grow at more than 13% CAGR from 2019 to 2028. It is expected to reach above USD 15.11 billion by 2028 from a little above USD 3.96 billion in 2019. Smart Containers Market https://exactitudeconsultancy.com/reports/824/smart-containers-market/ The Global Smart Containers Market size is expected to grow at more than 17% CAGR from 2015 to 2025. It is expected to reach above USD 7.1 billion by 2025 from USD 1.6 billion in 2015. In-Wheel Motors Market https://exactitudeconsultancy.com/reports/2832/in-wheel-motors-market/ The global in-wheel motors market is expected to grow at 20% CAGR from 2022 to 2029. It is expected to reach above USD 2,741.46 million by 2029 from USD 541 million in 2020. Transportation Telematics Market https://exactitudeconsultancy.com/reports/3118/transportation-telematics-market/ The global transportation telematics market is expected to grow at 20% CAGR from 2022 to 2029. It is expected to reach above USD 66.04 billion by 2029 from USD 12.79 billion in 2020. Actuators Market https://exactitudeconsultancy.com/reports/4683/actuators-market/ The global actuators market size is expected to grow at 8.5% CAGR from 2022 to 2029. It is expected to reach above USD 112.74 billion by 2029 from USD 54.1 billion in 2020. Marine Lubricants Market https://exactitudeconsultancy.com/reports/3126/marine-lubricants-market/ The global marine lubricants market is expected to grow at a 2.4% CAGR from 2022 to 2029. It is expected to reach above USD 11.9 billion by 2029 from USD 6.8 billion in 2020. Alloy Wheels Market https://exactitudeconsultancy.com/reports/1430/alloy-wheels-market/ The global alloy wheels market was valued at USD 15 Billion in 2019 and is projected to reach USD 24.3 Billion by 2028, growing at a CAGR of 5% from 2019 to 2028. Headlamps Market https://exactitudeconsultancy.com/reports/965/headlamps-market/ The Global Headlamps Market is expected to grow at more than 3.96% CAGR from 2018 to 2025. It is expected to reach above USD 229 million by 2025 from a little above USD 176 million in 2018. Automotive Haptic Technology Market https://exactitudeconsultancy.com/reports/2608/automotive-haptic-technology-market/ The global automotive haptic technology market is expected to grow at 11% CAGR from 2022 to 2029. It is expected to reach above USD 5.76 billion by 2029 from USD 2.25 billion in 2020. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Washington, D.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- RAINN released the following statement after former Rep. Matt Gaetz announced that he has withdrawn from consideration to be Attorney General: “Make no mistake that this decision was in response to survivors and advocates using their voices to demand accountability, and because of the courage of members of Congress who refused to endorse this pick,” said Scott Berkowitz , RAINN president and founder. “RAINN called for the sex trafficking allegations against Gaetz to be thoroughly investigated since this nomination was announced. We could not reconcile the Justice Department — the department responsible for providing survivors with avenues for justice — being led by an alleged abuser of women. RAINN heard you, Matt Gaetz heard you, and survivors will not be silenced.” “For the other nominees facing allegations of sexual assault: We ask the relevant Senate committees to gather and consider all the facts before voting on any such nomination,” said Berkowitz. “Sexual assault happens to someone in the U.S. every 68 seconds. It occurs in our places of business, our schools, our doctors’ offices; urban or rural, in private and in public. Every single political appointee will have to confront their role in sexual assault response, prevention and recovery. And it starts now.” “This is not the end,” said Jennifer Simmons Kaleba , vice president of communications for RAINN. “Mr. Gaetz may have stepped down, but he is not the only nominee facing sexual assault allegations. We’re seeing what survivors already know—when individuals, especially those nominated for some of the highest public offices in our nation, are accused of sexual assault and are promoted without fully considering the allegations, everyone suffers. Not only does this reinforce the important role the Senate plays in vetting and voting on nominations, it underscores how critical it is that survivors speak up, speak out and be heard. Change is possible — we saw it happen today.” For any survivors for whom this is a difficult time, RAINN’s National Sexual Assault Hotline stands ready with free, confidential, 24/7 support for survivors and their loved ones in English and in Spanish at 800.656.HOPE (4673) and hotline.RAINN.org .” ( Note: Berkowitz and Simmons Kaleba are available for reaction, comment and interview) ### About RAINN RAINN , the nation's largest anti-sexual violence organization, created and operates the National Sexual Assault Hotline. RAINN also carries out programs to prevent sexual violence, help survivors, help organizations improve their sexual assault prevention and response programs, and ensure that perpetrators are brought to justice. If you or someone you know has experienced sexual violence, free, confidential help is available 24/7 by calling 800.656.HOPE (4673) or visiting hotline.RAINN.org .

We will comprehensively resolve land disputes through revenue meetings: AP CM Naidu3D Mapping and Modeling Market Size, Share, New Opportunities, Unleashing Growth Potential, Current Trends and Future Analysis & Forecast - 2028

Alibaba: China Woes Will Subside And This Undervalued Powerhouse Will Thrive

AP Business SummaryBrief at 1:14 p.m. EST